Comparative Efficacy of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Treatment Response in Atopic Dermatitis at Varying Treatment Continuance Rates. J of Skin [Internet]. 2025 Jan. 13 [cited 2025 May 30];9(1):s519. Available from: https://skin.dermsquared.com/skin/article/view/3158